Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
12.28.20
Pillsbury client Accelerated Infection Protection Technologies, Inc. (AIPT) announced the development of a new intervention product specifically designed to reduce the spread of the COVID-19 virus.
According to the AIPT, studies have shown that the product, called Sustania is potentially a safe, effective, and rapidly deployable tool in the fight against COVID-19. In vitro testing of Sustania demonstrated its ability to kill greater than 99.7 % of virus.
Upon regulatory approval, Sustania will be available in a personal-sized nasal applicator that could minimize the opportunity for infection at the tip of the nasal cavity, and in an oral wash shown effective in killing the COVID-19 virus in in vitro studies.
AIPT plans to seek expedited authorization for Sustania use in the EU under the COVID-19 emergency provisions. AIPT will seek full CE Mark certification in 2021 and plans to initiate discussions with the U.S. Food & Drug Administration for COVID-19 Emergency Use Authorization in January 2021.
The development and launch teams for Sustania include Ceutical Labs; The Latham Biopharm Group; Pillsbury, as legal counsel; and Morgan Da Vinci Group. The parent company of Accelerated Infection Protection Technologies is a member of the Texas Healthcare BioScience Institute. AIPT has filed provisional patents in the U.S. establishing a priority date for global patent protection.
The Pillsbury team was led by Barry Burgdorf in Austin included Corporate senior law clerk Anthony Krueger and Litigation associate Elin Isenhower, Intellectual Property partner Josh Tucker and technical consultant Ehsan Moaseri, and Trademark partner Patrick Jennings.